Nakamura Tatsuya, Azami Yusuke, Ono Takashi, Yamaguchi Hisashi, Hayashi Yuichiro, Suzuki Motohisa, Hatayama Yoshiomi, Tsukiyama Iwao, Hareyama Masato, Kikuchi Yasuhiro, Takayama Kanako, Fuwa Nobukazu
Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama
Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Koriyama.
Jpn J Clin Oncol. 2016 Jan;46(1):46-50. doi: 10.1093/jjco/hyv160. Epub 2015 Nov 3.
This study aimed to evaluate the efficacy and toxicity of proton beam therapy combined with cisplatin intra-arterial infusion via a superficial temporal artery as treatment for maxillary sinus carcinoma.
Twenty-six patients with confirmed maxillary sinus carcinoma were enrolled in this study from May 2009 to April 2011. Patients underwent proton beam therapy and intra-arterial infusion chemotherapy with cisplatin.
The median total dose was 70.4 GyE per 32 fractions, and the median dose of cisplatin was 300 mg/body for six cycles of intra-arterial infusion. The 3-year overall survival rate was 58% for all patients (n = 26), 58% for patients with stage T4 disease (n = 12), 57% for patients with <Stage T3 disease (n = 14), 66% for patients with squamous cell carcinoma (n = 15) and 45% for patients with non-squamous cell carcinoma (n = 11). Two patients developed non-hematologic side effects such as Grade 3 radiation dermatitis, one developed osteonecrosis and one developed brain necrosis. Ocular/visual problems occurred in three patients, which included Grade 4 retinopathy and Grade 3 cataract in one and two patients, respectively.
Proton beam therapy combined with cisplatin intra-arterial infusion administered via a superficial temporal artery appears to be safe and effective for maxillary sinus carcinoma.
本研究旨在评估质子束治疗联合经颞浅动脉顺铂动脉内灌注治疗上颌窦癌的疗效和毒性。
2009年5月至2011年4月，26例确诊为上颌窦癌的患者纳入本研究。患者接受质子束治疗和顺铂动脉内灌注化疗。
总剂量中位数为每32分次70.4 GyE，顺铂动脉内灌注6个周期的剂量中位数为300 mg/体。所有患者（n = 26）的3年总生存率为58%，T4期患者（n = 12）为58%，<T3期患者（n = 14）为57%，鳞状细胞癌患者（n = 15）为66%，非鳞状细胞癌患者（n = 11）为45%。2例出现非血液学副作用，如3级放射性皮炎，1例发生骨坏死，1例发生脑坏死。3例患者出现眼部/视觉问题，其中1例为4级视网膜病变，2例分别为3级白内障。
质子束治疗联合经颞浅动脉顺铂动脉内灌注治疗上颌窦癌似乎安全有效。
